Silibinin as potential tool againstSARS‐Cov‐2: In silico spikereceptor‐bindingdomain and main protease molecular docking analysis, and in vitro endothelial protective effects

The endothelin system as target for therapeutic interventions in cardiovascular and renal disease

(2020) Eray Eroglu et al.   CLINICA CHIMICA ACTA

Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines

(2020) Xin Liu et al.   Journal of Genetics and Genomics

Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

(2020) Chunyan Yi et al.   Cellular & Molecular Immunology

Structural and Simulation analysis of hot spot residues interactions of SARS-CoV 2 with Human ACE2 receptor

(2020) Ganesh Kumar Veeramachaneni et al.   JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

(2020) Fei Zhou et al.   LANCET

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

(2020) Zhenming Jin et al.   NATURE

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

(2020) Maximilian Ackermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants

(2020) Muhammad Tahir ul Qamar et al.   Journal of Pharmaceutical Analysis

A link between inflammation and thrombosis in atherosclerotic cardiovascular diseases: Clinical and therapeutic implications

(2020) Evangelos Oikonomou et al.   ATHEROSCLEROSIS

Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad

(2020) Sakir Ahmed et al.   CLINICAL RHEUMATOLOGY

Correlation between monocyte chemoattractant protein-1/chemokine (C-C motif) ligand 2 and coronary plaque characteristics

(2020) Meng Li et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Why not consider an endothelin receptor antagonist against SARS‐CoV‐2?

(2020) S. Javor et al.   MEDICAL HYPOTHESES

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study

(2020) George Goshua et al.   Lancet Haematology

Endothelial dysfunction in COVID-19: Current findings and therapeutic implications

(2020) Matthias P. Nägele et al.   ATHEROSCLEROSIS

IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome

(2020) Sujin Kang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management

(2020) Mouhamed Yazan Abou-Ismail et al.   THROMBOSIS RESEARCH

Silybin B and Cianidanol Inhibit M pro and Spike Protein of SARS-CoV-2: Evidence from in Silico Molecular Docking Studies

(2020) Rashi Srivastava et al.   CURRENT PHARMACEUTICAL DESIGN

Structure-based identification of potential SARS-CoV-2 main protease inhibitors

(2020) Shama Khan et al.   JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS

Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia

(2020) Andrew Hsu et al.   THROMBOSIS RESEARCH

Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review

(2019) Vahid Soleimani et al.   PHYTOTHERAPY RESEARCH

Silibinin protects human endothelial cells from high glucose-induced injury by enhancing autophagic response

(2018) Aysa Rezabakhsh et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Selenoprotein S Attenuates Tumor Necrosis Factor-α-Induced Dysfunction in Endothelial Cells

(2018) Siyuan Cui et al.   MEDIATORS OF INFLAMMATION

Correlation between plasma endothelin-1 levels and severity of septic liver failure quantified by maximal liver function capacity (LiMAx test). A prospective study

(2017) Magnus F. Kaffarnik et al.   PLoS One

Immunotherapeutic implications of IL-6 blockade for cytokine storm

(2016) Toshio Tanaka et al.   Immunotherapy

pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures

(2015) Douglas E. V. Pires et al.   JOURNAL OF MEDICINAL CHEMISTRY

Impact of MCP -1 in Atherosclerosis

(2014) Juntang Lin et al.   CURRENT PHARMACEUTICAL DESIGN

Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking

(2013) Julie Blaising et al.   CELLULAR MICROBIOLOGY

Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice

(2011) Giovanni Li Volti et al.   Cardiovascular Diabetology

Effects of 17-Hydroxyprogesterone on Tumor Necrosis Factor- -Induced Hypertension During Pregnancy

(2009) S. D. Keiser et al.   AMERICAN JOURNAL OF HYPERTENSION

Silibinin and Related Compounds Are Direct Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase

(2009) Abdelhakim Ahmed–Belkacem et al.   GASTROENTEROLOGY

Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C

(2009) Roy L. Hawke et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells

(2009) Marco Trappoliere et al.   JOURNAL OF HEPATOLOGY

Silibinin Is a Potent Antiviral Agent in Patients With Chronic Hepatitis C Not Responding to Pegylated Interferon/Ribavirin Therapy

(2008) Peter Ferenci et al.   GASTROENTEROLOGY